KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $8.24.

  • Regeneron Pharmaceuticals' EPS (Basic) fell 351.29% to $8.24 in Q4 2025 from the same period last year, while for Dec 2025 it was $43.15, marking a year-over-year increase of 552.7%. This contributed to the annual value of $43.07 for FY2025, which is 530.56% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its EPS (Basic) stood at $8.24 for Q4 2025, which was down 351.29% from $14.09 recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EPS (Basic) ranged from a high of $29.51 in Q2 2021 and a low of $6.7 during Q1 2024
  • Its 5-year average for EPS (Basic) is $11.9, with a median of $10.74 in 2023.
  • In the last 5 years, Regeneron Pharmaceuticals' EPS (Basic) surged by 26031.75% in 2021 and then crashed by 7322.94% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EPS (Basic) (Quarter) stood at $20.98 in 2021, then crashed by 46.57% to $11.21 in 2022, then fell by 2.85% to $10.89 in 2023, then fell by 21.58% to $8.54 in 2024, then dropped by 3.51% to $8.24 in 2025.
  • Its EPS (Basic) was $8.24 in Q4 2025, compared to $14.09 in Q3 2025 and $13.24 in Q2 2025.